A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Funapide (Primary)
  • Indications Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 29 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2017 According to a Xenon Pharmaceuticals media release, the company will host a conference call and live audio webcast to discuss the topline results from this trial.
    • 27 Jun 2017 Primary endpoint ( Change from baseline in Numeric Rating Scale (NRS) to week 4) has not been met, according to a Teva Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top